Do Percutaneous Coronary Interventions of Chronic Total Occlusion Have a Different Impact on Thyroid Functions Compared to Non-Complex Percutaneous Coronary Interventions? <br> <br>.
This study assessed whether high levels of iodide administered during percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) differentially influenced thyroid function compared to PCI for non-complex coronary lesions. A total of 615 patients, 205 of whom underwent elective PCI for CTO lesions (Group I) and 410 of whom underwent elective, non-complex PCI, including non-CTO, non-bifurcation, non-calcified and non-tortuous (Group II) were enrolled in the study. Patients were monitored for development of incidental thyroid dysfunction between one and six months after PCI. Patients in Group I was administered a median of 255 mL of contrast medium during PCI for CTO, whereas a median of 80 mL of contrast medium was administered to patients in Group II during non-complex PCI (p = 0.001). Ten (5.4%) of the 186 euthyroid patients in Group I developed subclinical hyperthyroidism, while 19 (5%) of the 379 euthyroid patients in Group II developed subclinical hyperthyroidism (p = 0.854). However, 7 (50%) of the 14 subclinical hyperthyroid patients in Group I developed overt hyperthyroidism, whereas 3 (12%) of the 25 subclinical hyperthyroid patients in Group II developed overt hyperthyroidism (p = 0.019). In euthyroid patients, PCI for coronary CTO lesions did not increase the risk for subclinical hyperthyroidism compared to PCI for non-complex coronary lesions. However, in patients with subclinical hyperthyroidism at baseline, PCI for coronary CTO lesions significantly increased the development of overt hyperthyroidism compared to PCI for non-complex coronary lesions. <br> <br>.